GB1530201A — Process for the preparation of aminoglycoside antibiotics and intermediates therefor
Assigned to Pfizer Inc · Expires 1978-10-25 · 48y expired
What this patent protects
The kanamycin derivatives of formula I, in which R is an amino or hydroxyl group and R<1> is an alkyl group optionally substituted by hydroxyl and/or amino groups, are obtained by alkylation of the compounds of formula II, in which R<2> is H or a benzyl group, R<3&…
USPTO Abstract
The kanamycin derivatives of formula I, in which R is an amino or hydroxyl group and R<1> is an alkyl group optionally substituted by hydroxyl and/or amino groups, are obtained by alkylation of the compounds of formula II, in which R<2> is H or a benzyl group, R<3> is an acyl-protecting group and R<4> is a hydroxyl group or an NHR<3> group, followed by the removal of the R<3> groups and the benzyl group R<2>, where appropriate. The compounds of formula II are new intermediates which are obtained by acylation of a kanamycin A, B or a 3-N-benzylkanamycin A, protected on all its amino functional groups, followed by the removal of the protecting groups and the intramolecular migration of the acyl group from oxygen to nitrogen. <IMAGE>
Drugs covered by this patent
- Bylvay (ODEVIXIBAT) · Ipsen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.